LUGPA 2023 Enduring CME Program   

Access the course by logging into LUGPALearn with your single sign on.  

Course Description 

Originally delivered as a live program at the LUGPA 2023 Annual Meeting, this enduring activity offers urology professionals continued access to expert insights and cutting-edge strategies that drive high-quality, patient-centered care. Participants will explore the latest therapies for urologic cancers, refine approaches to prostate cancer monitoring and treatment, and adopt best practices in bladder cancer therapy administration. The course also provides guidance on establishing a successful female sexual health program and reviews treatment options and outcomes for BPH. Additionally, it offers a forward-looking analysis of how artificial intelligence can be effectively integrated into urology practices to improve clinical and operational outcomes. 

Learning Objectives 

1. Evaluate the differences in therapies used to treat urologic cancers. 
2. Analyze the optimal way to monitor and test for the treatment prostate cancer. 
3. Adopt and develop best practices in the administration of bladder cancer therapies. 
4. Identify the clinical and operational components to establish a successful female sexual health program. 
5. Describe the various treatment options and outcomes for BPH. 
6. Review and appraise the use of artificial intelligence in a urology practice. 

Accreditation and Designation Statement  

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the LUPGA.  

PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians. PeerPoint Medical Education Institute designates the enduring format for this educational activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activities.  

The enduring approval period is: July 14, 2025 – July 14, 2028 

Accreditation and Designation Statements and Disclosure Report.pdf 

Included Recorded Sessions:  

Successful Bladder Cancer Programs: What you should be offering your patients today and tomorrow? 
Moderator: Tom Jayram, MD 
Panelists: Rian Dickstein, MD 

Michael B. Williams, MD 

Jonathan Henderson, MD 

Building a Successful Female Sexual Health Program/SPA 
Moderator: Guy Manetti, MD 
Panelists: Sarah Girardi, MD 

Anika Ackerman, MD 

What’s New in Radiation Oncology 
Presenter: Dan Spratt, MD 

Good, Bad and Ugly of NEW BPH Treatments 
Moderator: Gregg Eure, MD 
Panelists: Arpeet Shah, MD 
Kevin Zorn, MD 
Tom Mueller, MD 
David Sussman, MD 
 
Best Practices for Active Surveillance 
Moderator: Ben Lowentritt, MD 
Panelists: David Morris, MD 
Aaron Berger, MD 
Ronney Abaza, MD 
 
Artificial Intelligence in Urology 
Presenter: Jodi Maranchie, MD 
 
Generative Artificial Intelligence in Urology 
Presenter: Inderbir Gill, MD